C群脑膜炎奈瑟菌血清杀菌力试验的优化及其应用

目的 优化血清杀菌力试验方法,检测和分析A+C群脑膜炎球菌多糖疫苗接种前后人群血清对C群脑膜炎奈瑟菌(Nm)的杀菌抗体水平.方法 以C群Nm疫苗株(C11)和中国目前C群Nm流行株(053442)作为靶菌,国家Nm标准品测试血清为参考血清,选用Pel-Freez幼兔补体,确定靶菌最适工作浓度.122人接种A+C群脑膜炎球菌多糖疫苗前后分别采集血清标本,共244份,进行C群Nm杀菌抗体水平的检测.结果 菌株C11和053442均可作为靶菌用于血清杀菌力试验;靶菌的工作浓度为A 0.35(600 nm)的菌液稀释4×104倍;A+C群脑膜炎球菌多糖疫苗接种前,122份血清对C11和053442的杀菌抗体几何平均滴度(GMT)分别为1:1.75和1:2.63,人群抗体保护率分别为9.8%和17.2%,A+C群脑膜炎球菌多糖疫苗接种后,122份血清的杀菌抗体GMT和人群保护率均显著升高(P<0.01),对疫苗株和流行株的杀菌抗体GMT分别为1:483.73和1:412.57,保护率分别为100%和95.9%.结论 接种A+C群脑膜炎球菌多糖疫苗,能够显著提高人群对不同亚型的C群Nm的抵抗力,但仍需要针对不同的靶菌进行疫苗免疫效果的监测.

Study on the bactericidal antibody against Neisseria meningitidis serogroup C strains after immunization with a divalent polysaccharide (A plus C) vaccine

Objective To optimize the serum bactericidal assay (SBA) , detect and analyze the bactericidal antibody level against Neisseria meningitidis serogroup C strains after divalent polysaccharide (A plus C) vaccine immunization. Methods Two Neisseria meningitidis serogroup C strains, vaccine candidate strain (C11) and epidemic strain (053442), were selected as targets. The national Neisseria meningitidis standardized serum was used as reference serum. Pel-Freez infant rabbit complements was available. The optimized SBA method was used to detect bactericidal antibody against strain C11 and 053442 for 122 pairs of sera before and after immunization with a divalent polysaccharide (A and C) vaccine. Results The strain C11 and 053442 both could be used as targeted strain for SBA. The optimized concentration of targeted strain was achieved when a whole-cell suspension of 0.35 A at 600 nm was diluted 4×104 times. Before immunization, SBA geometric mean titers(GMT) of 122 sera against strain C11 and 053442 were 1: 1.75 and 1:2.63 respectively, and the protective rates were 9.8% and 17.2% respectively. After immunization, the GMTs and the protective rates of 122 sera both rose significantly (P<0.01), the GMTs against strain C11 and 053442 were 1:483.73 and 1:412.57 respectively. The protective rates against strain C11 and 053442 were 100% and 95.9% respectively. Conclusion Immunization with a divalent polysaccharide (A and C) vaccine could elevate remarkably the population SBA titer against Neisseria meningitidis serogroup C strains of different subtypes, but the surveillance of vaccine effect against different targeted strains remains necessary.